Solventum Co. (NYSE:SOLV) Holdings Lowered by Nuance Investments LLC

Nuance Investments LLC lowered its holdings in shares of Solventum Co. (NYSE:SOLV) by 17.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,356,217 shares of the company’s stock after selling 283,136 shares during the quarter. Solventum makes up 3.6% of Nuance Investments LLC’s portfolio, making the stock its 9th biggest holding. Nuance Investments LLC owned approximately 0.79% of Solventum worth $89,592,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Solventum by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 16,266,893 shares of the company’s stock valued at $1,074,591,000 after buying an additional 75,631 shares during the last quarter. Trian Fund Management L.P. lifted its stake in Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after purchasing an additional 1,765,676 shares in the last quarter. State Street Corp boosted its holdings in shares of Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Solventum by 4.0% during the third quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock valued at $232,608,000 after purchasing an additional 128,317 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC bought a new stake in shares of Solventum in the third quarter worth about $125,488,000.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Mizuho raised their price target on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. Piper Sandler boosted their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Wells Fargo & Company increased their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Bank of America upped their target price on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Finally, Morgan Stanley lifted their price target on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $79.86.

Solventum Price Performance

Shares of SOLV stock opened at $74.87 on Wednesday. The company’s 50-day simple moving average is $75.38 and its two-hundred day simple moving average is $71.73. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a one year low of $47.16 and a one year high of $85.92. The company has a market capitalization of $12.95 billion and a P/E ratio of 27.23.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.